TY - JOUR
T1 - Incidence of implantable cardioverter defibrillator therapy and mortality in primary and secondary prevention of sudden cardiac death
AU - Konstantino, Yuval
AU - Shafat, Tali
AU - Novack, Victor
AU - Novack, Lena
AU - Amit, Guy
N1 - Publisher Copyright:
© The Israel Medical Association.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Background: Implantable cardioverter defibrillators (ICDs) reduce mortality in patients implanted for primary and secondary prevention of sudden cardiac death. Data on the incidence of appropriate ICD therapies in primary vs. secondary prevention are limited. Objectives: To compare ICD therapies and mortality in primary vs. secondary prevention of sudden cardiac death. Methods: We conducted a retrospective analysis of 581 consecutive patients receiving an ICD for primary (66%) or secondary (34%) prevention indications. Results: During long-term follow-up, 29% of patients implanted for secondary prevention received appropriate ICD therapy vs. 18% implanted for primary prevention. However, the overall 7 year mortality rate was not significantly different between the two groups (26.9%, P = 0.292). Multivariate analysis showed that patients implanted for primary prevention had a significantly lower risk of appropriate ICD therapy even after adjustment for age, left ventricular ejection fraction < 0.35 and chronic renal failure (HR 1.63, 95%CI 1.10–2.41, P = 0.015). Conclusions: Patients implanted for secondary prevention were more likely to receive appropriate ICD therapy, with a significantly shorter time period from ICD implant to the first therapy. However, all-cause mortality was comparable between primary and secondary prevention groups.
AB - Background: Implantable cardioverter defibrillators (ICDs) reduce mortality in patients implanted for primary and secondary prevention of sudden cardiac death. Data on the incidence of appropriate ICD therapies in primary vs. secondary prevention are limited. Objectives: To compare ICD therapies and mortality in primary vs. secondary prevention of sudden cardiac death. Methods: We conducted a retrospective analysis of 581 consecutive patients receiving an ICD for primary (66%) or secondary (34%) prevention indications. Results: During long-term follow-up, 29% of patients implanted for secondary prevention received appropriate ICD therapy vs. 18% implanted for primary prevention. However, the overall 7 year mortality rate was not significantly different between the two groups (26.9%, P = 0.292). Multivariate analysis showed that patients implanted for primary prevention had a significantly lower risk of appropriate ICD therapy even after adjustment for age, left ventricular ejection fraction < 0.35 and chronic renal failure (HR 1.63, 95%CI 1.10–2.41, P = 0.015). Conclusions: Patients implanted for secondary prevention were more likely to receive appropriate ICD therapy, with a significantly shorter time period from ICD implant to the first therapy. However, all-cause mortality was comparable between primary and secondary prevention groups.
KW - Implantable cardioverter defibrillator (ICD)
KW - Primary prevention
KW - Secondary prevention
KW - Sudden cardiac death
UR - http://www.scopus.com/inward/record.url?scp=84955124086&partnerID=8YFLogxK
M3 - Article
C2 - 26897978
AN - SCOPUS:84955124086
SN - 1565-1088
VL - 17
SP - 760
EP - 763
JO - Israel Medical Association Journal
JF - Israel Medical Association Journal
IS - 12
ER -